Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 9:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Breast Clear all
Completed Phase 2 Interventional

Effects of Raloxifene on Hormone Levels

NCT00026962
View directory record Official record
Conditions
Breast Cancer
Interventions
measuring estradiol and progesterone levels in saliva
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Not applicable Interventional

Breastfeeding Education and Support Trial for Obese Women (BESTOW)

NCT01338727
View directory record Official record
Conditions
Exclusive Breastfeeding, Breastfeeding Initiation
Interventions
Breastfeeding Peer Counseling
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years and older · Female only
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Not applicable Interventional

Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer

NCT00308178
View directory record Official record
Conditions
Breast Cancer
Interventions
Abraxane
Drug
Lead sponsor
Harold J. Burstein, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2013 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Phase 2 Interventional Results available

TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer

NCT03093350
View directory record Official record
Conditions
Breast Cancer
Interventions
TAA-specific CTLs
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Jun 10, 2026, 9:39 AM EDT
Recruiting Phase 1 Interventional

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

NCT04222413
View directory record Official record
Conditions
Advanced Solid Tumors, Metastatic Pancreatic Cancer, Pediatric Solid Tumor, Advanced Breast Cancer, Malignant Peripheral Nerve Sheath Tumor, Colorectal Neoplasms
Interventions
Metarrestin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Fairway, Kansas • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Promoting Self-Management of Breast and Nipple Pain With Technology (PROMPT) for Breastfeeding Women Study

NCT05262920
View directory record Official record
Conditions
Breastfeeding, Exclusive, Pain, Acute, Maternal Distress, Parent-Child Relations, Self Efficacy
Interventions
The BSM Intervention, Attention Control
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Farmington, Connecticut • Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of SNX-1012 in the Treatment of Oral Mucositis

NCT00385515
View directory record Official record
Conditions
Stomatitis, Oral Mucositis
Interventions
SNX-1012 (meclocycline sulfosalicylate), placebo
Drug
Lead sponsor
Mucosal Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
Rancho Mirage, California • Bridgeport, Connecticut • Norwich, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated May 6, 2009 · Synced Jun 10, 2026, 9:39 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

COVID-19 Breastfeeding Guideline for African-Americans

NCT04476940
View directory record Official record
Conditions
Covid19, Exclusive Breastfeeding
Interventions
COVID-19 Breastfeeding Support
Behavioral
Lead sponsor
Meharry Medical College
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Phase 1 Interventional

Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer

NCT00650910
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib, Digoxin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Not applicable Interventional

Study of Health Promotion in Patients With Early-Stage Breast or Prostate Cancer

NCT00037024
View directory record Official record
Conditions
Breast Cancer, Depression, Fatigue, Malnutrition, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions
fatigue assessment and management, nutritional support, physical therapy, psychosocial assessment and care, quality-of-life assessment
Procedure
Lead sponsor
Duke University
Other
Eligibility
65 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Jun 10, 2026, 9:39 AM EDT
Completed No phase listed Observational

Epigenetics and Psychoneurologic Symptoms in Women With Breast Cancer

NCT01411943
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 81 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Newport News, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Jun 10, 2026, 9:39 AM EDT
Terminated Phase 2 Interventional Results available

Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer

NCT01934335
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
Vandetanib, Placebo
Drug · Other
Lead sponsor
Ronald Weigel
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin

NCT05395117
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5462, Midazolam, Rosuvastatin, Digoxin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Jun 10, 2026, 9:39 AM EDT
Completed No phase listed Observational

Retrospective Analysis of Veritas in Breast Reconstruction

NCT01454713
View directory record Official record
Conditions
Seroma, Necrosis, Infection
Interventions
Not listed
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
San Diego, California • Troy, Michigan • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Jun 10, 2026, 9:39 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

NCT02032823
View directory record Official record
Conditions
Breast Cancer
Interventions
Olaparib, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
368
States / cities
Anchorage, Alabama • Anchorage, Alaska • Gilbert, Arizona + 321 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 10, 2026, 9:39 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Study to Compare the Diagnostic Accuracy of Nuance Full-Field Digital Mammography to Screen-Film Mammography

NCT00942396
View directory record Official record
Conditions
Breast Cancer
Interventions
Full Field Digital Mammogram (Planmed Sophie Nuance)
Device
Lead sponsor
Planmed Oy
Industry
Eligibility
40 Years to 85 Years · Female only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Memphis, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Jun 10, 2026, 9:39 AM EDT
Completed No phase listed Observational Results available

Immediate Postmastectomy Breast Reconstruction (Strattice Breast)

NCT00619762
View directory record Official record
Conditions
Breast Cancer
Interventions
LTM - a porcine-based surgical mesh
Device
Lead sponsor
LifeCell
Industry
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Great Neck, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

NCT00834678
View directory record Official record
Conditions
Breast Cancer
Interventions
bendamustine, erlotinib, Maintenance erlotinib
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Phase 1 Interventional Results available

Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC

NCT01761240
View directory record Official record
Conditions
Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
Interventions
MORAb-066
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years to 99 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Phase 2 Interventional Results available

Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer

NCT00570323
View directory record Official record
Conditions
Breast Cancer
Interventions
Arimidex, Faslodex
Drug
Lead sponsor
Mothaffar Rimawi
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Phase 2 Interventional

Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer

NCT00146562
View directory record Official record
Conditions
Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer
Interventions
Darbepoetin Alfa, Pegfilgrastim, Paclitaxel, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
Harold J. Burstein, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
6
States / cities
Boston, Massachusetts • Lowell, Massachusetts • Peabody, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Phase 1 Interventional

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

NCT03517488
View directory record Official record
Conditions
Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Non-small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Mesothelioma, Neuroendocrine Carcinoma, Cervical Cancer, Small Cell Lung Carcinoma, Squamous Cell Carcinoma of the Anus, Castration-Resistant Prostate Carcinoma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Basal Cell Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Thymoma, Thymic Carcinoma, Squamous Cell Carcinoma of the Penis, Vulvar Carcinoma, Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy, Malignant Adnexal Neoplasms, Non-squamous Cell Salivary Gland Carcinoma
Interventions
XmAb20717
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
17
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Jun 10, 2026, 9:39 AM EDT
Not listed Phase 1 Interventional

Cardiac Safety Assessment Study of Picoplatin in Solid Tumors

NCT00710697
View directory record Official record
Conditions
Solid Tumors
Interventions
Picoplatin
Drug
Lead sponsor
Poniard Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2009 · Synced Jun 10, 2026, 9:39 AM EDT
Terminated Phase 2 Interventional

High-Dose Esterified Estrogens in Treating Postmenopausal Women With Metastatic Breast Cancer That Has Failed Previous Hormone Therapy

NCT00131924
View directory record Official record
Conditions
Breast Cancer
Interventions
esterified estrogens
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Jun 10, 2026, 9:39 AM EDT